We will be comparing the differences between Genmab A/S (NASDAQ:GMAB) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) as far as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EyePoint Pharmaceuticals Inc.||2||10.92||N/A||-1.37||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Genmab A/S and EyePoint Pharmaceuticals Inc.
Table 2 represents Genmab A/S (NASDAQ:GMAB) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|EyePoint Pharmaceuticals Inc.||0.00%||-336.6%||-122.8%|
Genmab A/S and EyePoint Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|EyePoint Pharmaceuticals Inc.||0||0||0||0.00|
Genmab A/S’s consensus price target is $23, while its potential upside is 15.64%.
Insider and Institutional Ownership
The shares of both Genmab A/S and EyePoint Pharmaceuticals Inc. are owned by institutional investors at 0% and 62% respectively. On the other hand, insiders held about 0.8% of EyePoint Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|EyePoint Pharmaceuticals Inc.||-4.79%||-18.71%||-16.77%||-34.43%||-38.5%||-26.46%|
For the past year Genmab A/S has 11.02% stronger performance while EyePoint Pharmaceuticals Inc. has -26.46% weaker performance.
Genmab A/S beats on 6 of the 8 factors EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company’s pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.